Related Experiment Video
Updated: Oct 30, 2025
06:07
Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells
Published on: June 13, 2020
6.9K
Preventing Colorectal Cancer through Prebiotics
Manijeh Mahdavi1, Isabelle Laforest-Lapointe2, Eric Massé1
1Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, QC J1E 4K8, Canada.
Microorganisms
|July 2, 2021
Summary
Prebiotics can help prevent colorectal cancer (CRC) by promoting beneficial gut bacteria and reducing inflammation. Understanding these mechanisms is crucial for clinical applications in CRC prevention and treatment.
Area of Science:
- Gastroenterology and Oncology
- Microbiome Research
- Nutritional Science
Background:
- Colorectal cancer (CRC) incidence is rising globally, linked to industrialization, lifestyle changes, and gut dysbiosis.
- Gut dysbiosis, an imbalance in gut microbiota, is associated with increased CRC risk.
- Prebiotics offer a potential strategy to counteract dysbiosis and its pro-cancer effects.
Purpose of the Study:
- To review the role of prebiotics in preventing and treating colorectal cancer.
- To explore the mechanisms by which prebiotics influence CRC development.
- To highlight the importance of gut microbiome modulation in CRC management.
Main Methods:
- Literature review of experimental studies on prebiotics and CRC.
- Analysis of gut microbiome alterations in response to prebiotic intervention.
- Examination of cellular and immunological mechanisms related to prebiotic effects.
Main Results:
- Prebiotics demonstrate a protective effect against CRC progression in experimental models.
- Prebiotics promote beneficial bacteria, enhancing short-chain fatty acid (SCFA) production.
- Prebiotics support anti-inflammatory responses and intestinal barrier integrity.
Conclusions:
- Prebiotics show significant promise in the prevention and treatment of colorectal cancer.
- Modulating gut microbiota with prebiotics is a viable strategy for CRC management.
- Further research is needed to fully elucidate clinical applications of prebiotics in CRC.
Related Concept Videos
02:59Cancer Prevention
7.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.1K
01:21Drugs for Treatment of Constipation-Predominant IBS
419
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
419
01:17Drugs for Treatment of Diarrhea-Predominant IBS
383
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
383
01:29Drugs for Treatment of Ulcerative Colitis in IBD
282
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
282
01:17Chronic Bowel Disorders: Introduction
580
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
580
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
403
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
403